Current Updates on the Role of MicroRNA in the Diagnosis and Treatment of Neurodegenerative Diseases

Copyright© Bentham Science Publishers; For any queries, please email at epubbenthamscience.net..

BACKGROUND: MicroRNAs (miRNA) are small noncoding RNAs that play a significant role in the regulation of gene expression. The literature has explored the key involvement of miRNAs in the diagnosis, prognosis, and treatment of various neurodegenerative diseases (NDD), such as Alzheimer's disease (AD), Parkinson's disease (PD), and Huntington's disease (HD). The miRNA regulates various signalling pathways; its dysregulation is involved in the pathogenesis of NDD.

OBJECTIVE: The present review is focused on the involvement of miRNAs in the pathogenesis of NDD and their role in the treatment or management of NDD. The literature provides comprehensive and cutting-edge knowledge for students studying neurology, researchers, clinical psychologists, practitioners, pathologists, and drug development agencies to comprehend the role of miRNAs in the NDD's pathogenesis, regulation of various genes/signalling pathways, such as α-synuclein, P53, amyloid-β, high mobility group protein (HMGB1), and IL-1β, NMDA receptor signalling, cholinergic signalling, etc. Methods: The issues associated with using anti-miRNA therapy are also summarized in this review. The data for this literature were extracted and summarized using various search engines, such as Google Scholar, Pubmed, Scopus, and NCBI using different terms, such as NDD, PD, AD, HD, nanoformulations of mRNA, and role of miRNA in diagnosis and treatment.

RESULTS: The miRNAs control various biological actions, such as neuronal differentiation, synaptic plasticity, cytoprotection, neuroinflammation, oxidative stress, apoptosis and chaperone-mediated autophagy, and neurite growth in the central nervous system and diagnosis. Various miRNAs are involved in the regulation of protein aggregation in PD and modulating β-secretase activity in AD. In HD, mutation in the huntingtin (Htt) protein interferes with Ago1 and Ago2, thus affecting the miRNA biogenesis. Currently, many anti-sense technologies are in the research phase for either inhibiting or promoting the activity of miRNA.

CONCLUSION: This review provides new therapeutic approaches and novel biomarkers for the diagnosis and prognosis of NDDs by using miRNA.

Medienart:

E-Artikel

Erscheinungsjahr:

2024

Erschienen:

2024

Enthalten in:

Zur Gesamtaufnahme - volume:24

Enthalten in:

Current gene therapy - 24(2024), 2 vom: 18., Seite 122-134

Sprache:

Englisch

Beteiligte Personen:

Saleem, Ammara [VerfasserIn]
Javed, Maira [VerfasserIn]
Akhtar, Muhammad Furqan [VerfasserIn]
Sharif, Ali [VerfasserIn]
Akhtar, Bushra [VerfasserIn]
Naveed, Muhammad [VerfasserIn]
Saleem, Uzma [VerfasserIn]
Baig, Mirza Muhammad Faran Ashraf [VerfasserIn]
Zubair, Hafiz Muhammad [VerfasserIn]
Bin Emran, Talha [VerfasserIn]
Saleem, Mohammad [VerfasserIn]
Ashraf, Ghulam Md [VerfasserIn]

Links:

Volltext

Themen:

Alzheimer’s disease
Anti-miRNA
Huntington’s disease.
Journal Article
MicroRNA
MicroRNAs
Neurodegenerative diseases
Neuroinflammation
Parkinson’s disease
Review

Anmerkungen:

Date Completed 30.01.2024

Date Revised 30.01.2024

published: Print

Citation Status MEDLINE

doi:

10.2174/0115665232261931231006103234

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

NLM363534199